Down syndrome sits at the center of this dementia and brain health question.

Yes, adults with Down syndrome are actively participating in clinical trials aimed at preventing Alzheimer’s disease—and their involvement is reshaping how scientists approach dementia prevention for everyone. More than 80% of adults with Down syndrome may experience dementia by age 65, a rate far exceeding that of the general population.

What makes their participation particularly valuable is that by age 40, virtually all individuals with Down syndrome have Alzheimer’s disease neuropathology—the biological hallmark of the disease—because they carry three copies of chromosome 21, which contains the amyloid precursor protein (APP) gene. This genetic reality means researchers can study Alzheimer’s development in a predictable, genetically homogeneous group, offering insights impossible to gain elsewhere. This article explores the ongoing research efforts, the clinical trials recruiting participants with Down syndrome, and why this population represents both a research opportunity and a moral imperative to find preventive treatments.

Why Adults With Down Syndrome Are Leading Alzheimer’s Prevention Research
The Biological Clock: Alzheimer’s Pathology in Down Syndrome
Active Clinical Trials Recruiting Adults With Down Syndrome
Measuring Cognitive and Biological Changes
Barriers and Ethical Considerations
What Down Syndrome Research Reveals About Alzheimer’s Prevention
The Future of Alzheimer’s Prevention for People With Down Syndrome
Conclusion

Why Adults With Down Syndrome Are Leading Alzheimer’s Prevention Research

People with Down syndrome represent what experts call “the largest genetically defined population at risk for Alzheimer’s disease.” Unlike the general population, where Alzheimer’s develops unpredictably across many decades with highly variable genetic backgrounds, individuals with Down syndrome have a clear, consistent trigger: the triplication of the APP gene. This genetic redundancy leads to overproduction of amyloid precursor protein, which accumulates in the brain as amyloid plaques—a primary driver of Alzheimer’s pathology. The consistency and predictability make Down syndrome a uniquely powerful research model. For researchers, this represents an enormous advantage.

In typical Alzheimer’s prevention trials conducted in older adults without Down syndrome, investigators struggle with natural variation: some people develop pathology slowly, others rapidly; some remain cognitively intact despite significant brain changes, while others decline sharply. But in the Down syndrome population, the biological timeline is remarkably uniform. A 45-year-old with Down syndrome and a 50-year-old with Down syndrome are at far more similar risk stages than a 65-year-old and 75-year-old in the general population. This reduces the sample sizes needed to detect whether preventive treatments work, accelerates the pace of research, and allows scientists to test drugs decades before they would typically emerge as treatments for older adults.

Why Adults With Down Syndrome Are Leading Alzheimer's Prevention Research

The Biological Clock: Alzheimer’s Pathology in Down Syndrome

The biological story behind Down syndrome and Alzheimer’s begins with chromosome 21. In typical development, humans inherit one copy of chromosome 21 from each parent. People with Down syndrome inherit three copies—a condition called trisomy 21. Chromosome 21 contains the gene for amyloid precursor protein (APP). With three copies instead of two, cells produce roughly 50% more APP, and this excess accumulates over decades as amyloid plaques and tau tangles in the brain.

The timeline is sobering: by age 40, neuropathological changes are essentially universal in the Down syndrome population. This means a person with Down syndrome at age 40 typically has the same brain pathology found in an 85-year-old without Down syndrome in the general population. However, cognitive symptoms may not emerge until later, sometimes not until the 50s or 60s. This lag between pathology and symptoms is crucial for prevention research—it creates a window in which interventions might slow or halt cognitive decline before it becomes noticeable. researchers can enroll younger, cognitively intact adults with Down syndrome who already have the neuropathology and track whether preventive treatments keep them cognitively stable longer.

Active Clinical Trials Recruiting Adults With Down Syndrome

The National Institute on Aging (NIA) and affiliated research institutions have invested significantly in building the infrastructure for Down syndrome Alzheimer’s trials. Several major studies are now enrolling. The HERO Study, run by Ionis Pharmaceuticals, represents one of the first dedicated prevention trials. Launched in 2025, HERO targets amyloid precursor protein directly using antisense technology—essentially blocking cells from making as much APP. The trial is enrolling 30 participants with Down syndrome across multiple U.S. and European sites, with an expected duration of two years. The first participant was dosed in 2025, marking a watershed moment for the field.

A second trial, ALADDIN, is launching in late 2025 and will investigate donanemab, an FDA-approved monoclonal antibody that clears amyloid plaques from the brain. Both trials represent the most advanced and direct attempts to prevent Alzheimer’s in the Down syndrome population to date. Alongside these treatment trials, infrastructure studies are building the research foundation. The Trial-Ready Cohort for Down Syndrome (TRC-DS) enrolls healthy adults ages 25–55 with Down syndrome for regular monitoring with blood tests and brain imaging. This cohort pre-screens participants for future Alzheimer’s prevention trials and establishes baseline data on cognitive and biomarker trajectories. Similarly, the Alzheimer’s Biomarkers Consortium – Down Syndrome (ABC-DS), which began enrolling in September 2020, aims to enroll 500 participants to identify blood and brain imaging biomarkers that can track Alzheimer’s progression. These biomarkers are essential: they allow researchers to detect whether a drug is slowing pathology even before cognitive symptoms appear, accelerating the path to approval.

Active Clinical Trials Recruiting Adults With Down Syndrome

Measuring Cognitive and Biological Changes

Tracking Alzheimer’s in people with Down syndrome requires specialized tools. The Cognitive Scale for Down Syndrome (CS-DS) is a validated assessment designed specifically to detect longitudinal cognitive decline in this population. Unlike general cognitive tests, which may be poorly suited to people with intellectual disabilities, the CS-DS measures domains of cognition that tend to decline first in Down syndrome Alzheimer’s, such as conceptual reasoning and adaptive functioning. But cognitive testing alone is insufficient.

Researchers increasingly rely on biomarkers—measurable signs of disease in blood and cerebrospinal fluid that reflect underlying pathology. Blood tests can now measure phosphorylated tau and amyloid levels, giving researchers a window into brain changes without requiring invasive procedures. Brain imaging with positron emission tomography (PET) and magnetic resonance imaging (MRI) visualizes amyloid and tau accumulation. A limitation of biomarker approaches, however, is cost and accessibility: not all participants have reliable access to imaging centers or regular phlebotomy services, particularly in rural areas. Research sites must invest in mobile services or partnerships with local hospitals to maximize enrollment and retention.

Barriers and Ethical Considerations

Enrolling adults with Down syndrome in clinical trials introduces unique challenges that researchers must navigate carefully. Many adults with Down syndrome have intellectual disabilities affecting their ability to provide informed consent. Ethical review boards require that investigators ensure participants understand what the study involves, the potential risks and benefits, and that they can withdraw at any time. This often requires simplified informed consent documents, extra time for explanation, and involvement of family members or guardians—steps that are ethically appropriate but administratively demanding.

There is also a historical undercurrent of concern: people with intellectual disabilities have historically been excluded from medical research or, in darker chapters, exploited within it. Current protections exist for good reason. However, this history can make families hesitant to enroll their relatives, even in well-designed, ethically sound trials. Overcoming this reluctance requires transparency, community engagement, and demonstrated commitment to participant safety and autonomy. Sites that have built trusted relationships with Down syndrome advocacy organizations report higher enrollment rates and lower dropout rates.

What Down Syndrome Research Reveals About Alzheimer’s Prevention

The insights gained from Down syndrome Alzheimer’s research extend far beyond the Down syndrome population. Amyloid and tau pathology drive Alzheimer’s in everyone, with or without Down syndrome. However, in Down syndrome, the pathology develops from a single, known genetic cause.

Interventions that prevent cognitive decline in this genetically homogeneous group may reveal how to prevent or slow Alzheimer’s more broadly. For example, if the HERO Study demonstrates that reducing APP levels slows cognitive decline in adults with Down syndrome, it would provide proof-of-concept for a strategy that could potentially help the millions of older adults with genetically influenced Alzheimer’s. Similarly, results from ALADDIN might clarify optimal timing and dosing of amyloid-clearing antibodies. These insights could reshape how neurologists approach prevention in older populations—informing new clinical practice guidelines, spurring additional trials in general populations, and potentially opening entirely new therapeutic pathways.

The Future of Alzheimer’s Prevention for People With Down Syndrome

The momentum building around Down syndrome Alzheimer’s research reflects a broader shift in how the field views prevention and precision medicine. Rather than waiting for dementia symptoms to appear, researchers are recognizing that intervening in the decades before cognitive decline becomes apparent offers the best chance of success. The Down syndrome population, with its predictable neurobiology, is leading this shift.

Looking ahead, the field is likely to see expanded trial networks, longer-term follow-up studies tracking participants for 5–10 years, and combination therapies—using two or more drugs simultaneously to target different pathways. The NIA’s sustained funding and INCLUDE Project infrastructure support suggest this research area will remain a priority. For people with Down syndrome and their families, these trials represent hope: a concrete pathway toward preventing one of the most serious health challenges facing their community.

Conclusion

Adults with Down syndrome are not merely research subjects in Alzheimer’s prevention trials—they are advancing one of neurology’s most pressing challenges. The same genetic reality that puts them at extraordinarily high risk—the triplication of chromosome 21 and its APP gene—makes them uniquely valuable for understanding how to prevent or slow Alzheimer’s in anyone. With trials like HERO, ALADDIN, and ongoing biomarker studies, researchers have launched a coordinated effort to test preventive approaches before cognitive decline takes hold.

For families affected by Down syndrome, these trials offer both immediate hope and long-term possibility. Participants contribute to research that may directly benefit themselves and their peers. For the broader field of neurology, findings from these trials may reshape how prevention is approached across the entire population facing Alzheimer’s risk. The path forward requires continued investment in research infrastructure, ethical enrollment practices, and partnership with Down syndrome communities—but the potential payoff—preventing one of the most debilitating aspects of aging—justifies the effort.